Five Below Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Five Below Inc trades at $214.73 (market cap $11.55B), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2.1× Five Below Inc's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| FIVE | ROIV | |
|---|---|---|
Market Cap | $11.55B | $24.72B |
Volume | 1,120,554 | 6,279,442 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $41.81 |
52-Week Low | $138.49 | $16.04 |
Typical Hold Time | 46 Days | 1 Days |
Enterprise Value | $12.40B | $20.99B |
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $209.56, up 2.61% today, with strong earnings beats in recent quarters and a bullish analyst consensus. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600 million buyback and board appointments.
Outlook remains positive with 60% analyst buy ratings and a $298.44 price target, though valuation premiums and execution risks persist. Key catalysts include Q3 2026 earnings and continued store expansion, while inflation and consumer spending trends pose near-term headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →